Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain.
Food Funct. 2021 Apr 21;12(8):3635-3646. doi: 10.1039/d0fo03160g. Epub 2021 Mar 31.
We aimed to study the effect of consuming an alcohol-free beer with modified carbohydrates composition (almost completely eliminating maltose and adding isomaltulose (16.5 g day) and resistant maltodextrin (5.28 g day)) in gut microbiome, compared to regular alcohol-free beer in subjects with T2DM or prediabetes and overweight/obesity. This is a pilot, randomized, double-blinded, crossover study including a sub-sample of a global study with 14 subjects: (a) consuming 66 cl day of regular alcohol-free beer for the first 10 weeks and 66 cl day of modified alcohol-free beer for the next 10 weeks; (b) the same described intervention in opposite order. BMI homogeneously decreased after both interventions. Glucose and HOMA-IR significantly decreased just after the participants consumed modified alcohol-free beer. These findings were in the same line as those reported in the global study. Dominant bacteria at baseline were Bacteroidetes, Firmicutes, Proteobacteria and Tenericutes. Parabacteroides, from the Porphymonadaceae family, resulted as the feature with the greatest difference between beers (ANCOM analysis, W = 15). Feature-volatility analysis confirmed the importance of Parabacteroides within the model. Alcohol-free beers consumption resulted in an enhancement of pathways related to metabolism according to PICRUSt analysis, including terpenoid-quinone, lipopolysaccharides and N-glycan biosynthesis. Thus, an alcohol-free beer including the substitution of regular carbohydrates for low doses of isomaltulose and the addition of maltodextrin within meals significantly impacts gut microbiota in diabetic subjects with overweight or obesity. This could, at least partially, explain the improvement in insulin resistance previously found after taking modified alcohol-free alcohol.Clinical Trial Registration: Registered under ClinicalTrials.gov identifier no. NCT03337828.
我们旨在研究与常规无酒精啤酒相比,在 T2DM 或糖尿病前期和超重/肥胖受试者中,饮用一种碳水化合物组成经过改良的无酒精啤酒(几乎完全消除麦芽糖,添加异麦芽酮糖(16.5 克/天)和抗性麦芽糊精(5.28 克/天))对肠道微生物组的影响。这是一项先导、随机、双盲、交叉研究,包括一项全球研究的子样本,共有 14 名受试者:(a)前 10 周每天饮用 66 cl 常规无酒精啤酒,接下来 10 周每天饮用 66 cl 改良无酒精啤酒;(b)以相反顺序进行相同的干预。两种干预后 BMI 均均匀下降。仅在参与者饮用改良无酒精啤酒后,血糖和 HOMA-IR 显著下降。这些发现与全球研究报告的结果一致。基线时优势菌为拟杆菌门、厚壁菌门、变形菌门和无壁菌门。拟杆菌科的 Parabacteroides 是两种啤酒之间差异最大的特征(ANCOM 分析,W = 15)。特征-挥发性分析证实了 Parabacteroides 在模型中的重要性。无酒精啤酒的消费导致根据 PICRUSt 分析与代谢相关的途径增强,包括萜类醌、脂多糖和 N-聚糖生物合成。因此,在超重或肥胖的糖尿病受试者中,餐中用低剂量异麦芽酮糖替代常规碳水化合物并添加麦芽糊精的无酒精啤酒显著影响肠道微生物群。这至少可以部分解释先前发现的在摄入改良无酒精啤酒后胰岛素抵抗改善的原因。临床试验注册:在 ClinicalTrials.gov 标识符下注册 no. NCT03337828。